Printer Friendly Version

    Dr. Zhibin Li is an Associate in the New York office of Locke Lord LLP. Zhibin practices on intellectual property issues, with an emphasis on pharmaceutical Hatch-Waxman litigation. Zhibin has been involved in various aspects of such litigations, including non-infringement and invalidity contentions, fact discovery, preliminary injunction, expert report, and motion practice. Additionally, Zhibin has experience in patent preparation and prosecution.

    Zhibin’s experience spans a wide range of technical areas within the life sciences, including, for example, pharmaceuticals, chemistry, nanomaterials, polymers, biotechnology, and medical devices.

    Prior to joining the Firm, Zhibin was a Principal Scientist at Boehringer-Ingelheim Pharmaceuticals Inc., with research expertise in solid form (polymorphs, salts, and cocrystals) screening, and API crystallization. In addition to his pharmaceutical experience and chemistry training, Zhibin also has extensive experience in material characterization using scattering (neutron, X-ray, light), microscopic (TEM, SEM, AFM, and optical), and thermo (DSC, TGA) methods in understanding materials with sizes ranging from nano- to micro- scale.

    Zhibin is a co-inventor of four patents and an author/co-author of more than 30 scientific publications.

    Professional History

    • Principal Scientist, Boehringer-Ingelheim Pharmaceuticals, Inc., Ridgefield, CT. (2006-2015)
    • Post-doctoral Research Fellow, Department of Material Science and Engineering, University of Delaware, Newark, DE. (2004-2006)
    • Post-doctoral Research Fellow, Department of Chemistry, Rensselaer Polytechnic Institute, Troy, NY (2002-2003)

    Find News, Events, Notable Matters, and More

    Showing Results for



    Please understand that your communications with Locke Lord LLP through this website do not constitute or create an attorney-client relationship with Locke Lord LLP. Any information you send to Locke Lord LLP through this website is on a non-confidential and non-privileged basis. Therefore, do not send or include any information in your email that you consider to be confidential or privileged.